Tag Archives: TRVN

Top Gold Stocks To Own For 2019

Small cap US Gold Corp (NASDAQ: USAU) has given an overall update on its Copper King property – an advanced stage gold and copper exploration and development project located in southeast Wyoming, 20 miles west of Cheyenne. The property comprises about 1,120 acres that include two Wyoming State Mining Leases and islocated entirely on state land -making for an easier permitting process and more affordable annual leases. The deposit is open in several directions, signifying additional exploration upside to its current gold resource, and has experienced extensive historical exploration. Since 1938, at least nine historic drilling campaigns by seven companies, plus the U.S. Bureau of Mines, have been conducted, with drilling by five different operators since 1970 confirming mineralization.

Top Gold Stocks To Own For 2019: DXP Enterprises Inc.(DXPE)

Advisors’ Opinion:

  • [By Logan Wallace]

    American Century Companies Inc. decreased its position in DXP Enterprises, Inc. (NASDAQ:DXPE) by 63.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 266,785 shares of the industrial products company’s stock after selling 454,667 shares during the quarter. American Century Companies Inc. owned approximately 1.54% of DXP Enterprises worth $10,391,000 at the end of the most recent reporting period.

  • [By Joseph Griffin]

    Press coverage about DXP Enterprises (NASDAQ:DXPE) has been trending somewhat positive on Thursday, Accern Sentiment reports. The research group rates the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. DXP Enterprises earned a coverage optimism score of 0.22 on Accern’s scale. Accern also assigned media headlines about the industrial products company an impact score of 44.8189875544661 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

  • [By Logan Wallace]

    Dynamic Technology Lab Private Ltd purchased a new stake in DXP Enterprises Inc (NASDAQ:DXPE) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 10,421 shares of the industrial products company’s stock, valued at approximately $406,000.

Top Gold Stocks To Own For 2019: WGL Holdings Inc(WGL)

Advisors’ Opinion:

  • [By Shane Hupp]

    Franklin Resources Inc. purchased a new stake in shares of WGL Holdings Inc (NYSE:WGL) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 28,373 shares of the utilities provider’s stock, valued at approximately $2,374,000. Franklin Resources Inc. owned about 0.06% of WGL as of its most recent SEC filing.

  • [By Stephan Byrd]

    WGL Holdings Inc (NYSE:WGL)’s share price reached a new 52-week high during trading on Thursday . The stock traded as high as $88.75 and last traded at $88.72, with a volume of 377688 shares traded. The stock had previously closed at $88.56.

Top Gold Stocks To Own For 2019: Trevena, Inc.(TRVN)

Advisors’ Opinion:

  • [By Logan Wallace]

    Here are some of the media headlines that may have effected Accern Sentiment’s analysis:

    Get Trevena alerts:

    Trevena, Inc. (TRVN): Stay Cool with Active Stock: (bitcoinpriceupdate.review) Key Aspects to Watch Out: Trevena, Inc. (TRVN) (connectinginvestor.com) Valuation Review and Technical Analysis of Crocs Inc (CROX) and Trevena Inc (TRVN) (postregistrar.com) Notable Investor’s Alert: Horizon Pharma Public Limited Company, (NASDAQ: HZNP), Trevena, Inc., (NASDAQ: TRVN) (globalexportlines.com) Hot Stock’s Highlights Trevena Inc (NASDAQ: TRVN) (stockspen.com)

    Trevena traded up $0.03, hitting $1.81, during mid-day trading on Wednesday, MarketBeat reports. 31,747 shares of the company were exchanged, compared to its average volume of 757,271. The firm has a market cap of $121.66 million, a P/E ratio of -1.50 and a beta of -0.54. The company has a debt-to-equity ratio of 0.35, a current ratio of 4.11 and a quick ratio of 4.11. Trevena has a twelve month low of $1.34 and a twelve month high of $3.10.

Top Gold Stocks To Own For 2019: Computer Task Group, Incorporated(CTG)

Advisors’ Opinion:

  • [By Stephan Byrd]

    These are some of the headlines that may have effected Accern’s scoring:

    Get Computer Task Group alerts:

    $88.05 Million in Sales Expected for Computer Task Group (CTG) This Quarter (americanbankingnews.com) CTG to Present at B. Riley Institutional Investor Conference on May 23 (finance.yahoo.com) Computer Task Group (CTG) Expected to Announce Earnings of $0.08 Per Share (americanbankingnews.com) ValuEngine Lowers Computer Task Group (CTG) to Hold (americanbankingnews.com)

    A number of brokerages recently commented on CTG. Zacks Investment Research lowered Computer Task Group from a “buy” rating to a “hold” rating in a research report on Friday, March 30th. ValuEngine lowered Computer Task Group from a “buy” rating to a “hold” rating in a research report on Wednesday, March 7th. Finally, Barrington Research reiterated a “hold” rating on shares of Computer Task Group in a research report on Friday, April 20th. Three research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $9.13.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Computer Task Group (CTG)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top Gold Stocks To Own For 2019: Bayer Aktiengesellschaft (BAYRY)

Advisors’ Opinion:

  • [By ]

    The last week has been depressing for Exelixis’ (EXEL) shareholders, as the stock dropped by around 13% and reached its 11-week low of $18.56 on May 10, 2018. The market was disappointed to see Exelixis’ Cotellic and Roche Holdings’ (OTCQX:RHHBY) Tecentriq failing to meet primary endpoint of improvement in overall survival as compared to Bayer’s (OTCPK:BAYRY) Stivarga in 2/3 line locally advanced or metastatic colorectal cancer indication. This trial, if successful, would have been a major advancement for the cobimetinib franchise and would have also been a major advancement in improving the sensitivity of cold tumors to immunotherapy.

  • [By Garrett Baldwin]

    Starbuck’s Corp.(Nasdaq: SBUX) Executive Chair Howard Schultz announced he will depart the company. Many are speculating he will pursue a career in politics and potentially seek the Democratic nomination for president in 2020. Schultz had previously denied any speculation around a role in government; but his recent comments suggest that “public service” will be a part of his future plans. Gold prices dipped below $1,300 per ounce as markets continue to speculate on the likelihood of additional interest rate hikes in 2018. We believe this is solid buying opportunity for investors. The reason why gold is going to get a nice boost: ongoing trade tensions between the United States and the rest of the globe. Money Morning Resource SpecialistPeter Krauth provides his insight on where gold prices are heading nextand how you can make big gains in the weeks ahead.
    Three Stocks to Watch Today: AAPL, TWTR, SCGLF
    Apple Inc. (Nasdaq: AAPL) is on the verge of becoming the world’s first $1 trillion company. The stock pushed above $192.60 per share in pre-market hours after its first day at the Worldwide Developers Conference. During the event, the company unveiled its new mobile operating system, called iOS 12. The firm also unveiled a suite of tools designed to combat technology addiction. Shares of Twitter Inc. (NYSE: TWTR) jumped nearly 4% on news that the social media company is about to join the S&P 500. The company will join on Thursday morning and will replace agribusiness giant Monsanto Co. (NYSE: MON). The news comes as Monsanto is in the final steps of its merger with German chemical giant Bayer AG (Nasdaq: BAYRY). Shares of Societe Generale SA (ADR) (OTCMKTS: SCGLF) are in focus after the U.S. Justice Department announced the French investment bank will pay $1.3 billion to settle two ongoing legal headaches. The company bribed Libyan officials and manipulated LIBOR, a benchmark interest rate on which most financing is based. Legg Mason Inc. (NYSE: L

  • [By Matthew Frankel]

    Berkshire Hathaway (NYSE:BRK-A) (NYSE:BRK-B), the conglomerate led by billionaire investor Warren Buffett, is officially receiving a nice windfall of cash. The acquisition of agricultural giant Monsanto (NYSE:MON) by Germany’s Bayer (NASDAQOTH:BAYRY) in an all-cash deal is putting more than $2.4 billion back into Berkshire’s coffers.

Top 10 Stocks To Buy For 2018

Visa (V) shares are soaring today after reporting earnings and revenue that easily topped the Street consensus.

Getty Images

Visa reported a profit of 86 cents a shares, topping forecasts for 78 cents, on revenue of $4.5 billion, ahead of estimates for $4.3 billion.

After review Visa’s earnings, Cowen’s George Mihalos and team write that Visa is “everywhere investors should want to be.” They explain why:

Visa reported very robust F1Q results and raised its FY17 outlook when adjusting for an incremental 1pt of F/X headwinds. We are raising our estimates and continue to believe there is upside to the companys outlook. Almost all key metrics showed signs of acceleration and we expect the momentum to continue. We expect the stock to be strong in tomorrow’s trading and remain very positive on the name.

Top 10 Stocks To Buy For 2018: Trevena, Inc.(TRVN)

Advisors’ Opinion:

  • [By Chris Lange]

    Trevena Inc. (NASDAQ: TRVN) reported positive results from two late-stage clinical trials that work to treat post-surgical pain. The company intends to submit these results to the FDA for a marketing approval agreement in the fourth quarter. Previously, oliceridine was approved for a breakthrough designation by the agency.

  • [By Lisa Levin] Gainers
    Trevena Inc (NASDAQ: TRVN) rose 10.8 percent to $3.60 in pre-market trading after dropping 4.97 percent on Wednesday.
    Yum China Holdings Inc (NYSE: YUMC) rose 10.2 percent to $31.05 in pre-market trading after the company reported upbeat earnings for its first quarter.
    Seres Therapeutics Inc (NASDAQ: MCRB) rose 9.1 percent to $11.39 in pre-market trading after dropping 5.26 percent on Wednesday.
    Plug Power Inc (NASDAQ: PLUG) rose 8.9 percent to $2.45 in pre-market trading after surging 73.08 percent on Wednesday.
    Coach Inc (NYSE: COH) rose 6.7 percent to $41.98 in pre-market trading. Coach named Ian Bickley as President, Global Business Development and Strategic Alliances.
    Sapiens International Corporation N.V. (NASDAQ: SPNS) shares rose 6.1 percent to $13.91 in pre-market trading after gaining 0.54 percent on Wednesday.
    Jazz Pharmaceuticals plc (NASDAQ: JAZZ) rose 6.1 percent to $149.15 in pre-market trading. Jazz Pharma reached a settlement with Hikma Pharma related to Xyrem patent case. Mizuho downgraded Jazz from Buy to Neutral.
    Interactive Brokers Group, Inc. (NASDAQ: IBKR) shares rose 6 percent to $36.72 in pre-market trading after declining 0.03 percent on Wednesday.
    Rewalk Robotics Ltd (NASDAQ: RWLK) rose 5.3 percent to $2.00 in pre-market trading after the company disclosed that the U.S. Department of Veterans Affairs purchased 28 added Exoskeleton Systems.
    Merrimack Pharmaceuticals Inc (NASDAQ: MACK) rose 5.1 percent to $3.29 in pre-market trading. Merrimack declared a $1.06 special dividend.
    BioTime, Inc. (NYSE: BTX) shares rose 4.8 percent to $3.50 in pre-market trading. BioTime, reported the formation of new subsidiary AgeX Therapeutics, Inc.
    Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) shares rose 4.8 percent to $12.26 in pre-market trading after gaining 0.69 percent on Wednesday.
    Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 3.6 percent to $39.15 in pre-market trading after the company posted better-than
  • [By Maxx Chatsko]

    Shares of clinical-stage biopharma Trevena (NASDAQ:TRVN) fell nearly 12% today after it reported full-year 2016 earnings. The pre-revenue company didn’t announce any surprises one way or the other. However, investors appear to be considering the near-term consequences of swelling expenses that won’t be offset by product sales anytime soon.

Top 10 Stocks To Buy For 2018: Global Eagle Entertainment Inc.(ENT)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Global Eagle Entertainment Inc (NASDAQ: ENT) were down around 31 percent to $4.30. Global Eagle named Jeff Leddy as Chief Executive Officer. Dave Davis resigned as CEO effective February 20, 2017.

  • [By Paul Ausick]

    Global Eagle Entertainment Inc. (NASDAQ: ENT) dropped about 1.4% Tuesday, to post a new 52-week low of $14.29 after closing at $14.49 on Friday. The stock’s 52-week high is $19.92. Volume was about 7 times the daily average of around 420,000 shares. The company’s CEO and CFO both resigned unexpectedly this morning.

Top 10 Stocks To Buy For 2018: Minerva Neurosciences, Inc(NERV)

Advisors’ Opinion:

  • [By Lisa Levin]

    Minerva Neurosciences Inc (NASDAQ: NERV) shares shot up 194 percent to $10.39 after the company revealed positive top line results from a prospective Phase IIb, 12-week, randomized, double-blind, placebo-controlled parallel clinical study evaluating the efficacy, safety and tolerability of MIN-101 in patients with negative symptoms of schizophrenia.

Top 10 Stocks To Buy For 2018: Avnet, Inc.(AVT)

Advisors’ Opinion:

  • [By Lisa Levin]

    Tech Data Corporation (NASDAQ: TECD) reached a deal with Avnet, Inc. (NYSE: AVT) enabling it to buy the latter's Technology Solutions business. The transaction comprises cash component of $2.4 billion and 2.785 million shares of Tech Data resulting in a total value of about $2.6 billion.

Top 10 Stocks To Buy For 2018: Coca-Cola Company (The)(KO)

Advisors’ Opinion:

  • [By Jack Delaney]

    He likes the company so much that The Coca-Cola Co. (NYSE: KO) is Berkshire’s 12th-largest holding.

    According to its website, Coke has paid a quarterly dividend since 1920 and has increased dividend payments in each of the last 55 years. Today, KO pays shareholders a dividend of $0.37, for a yield of 3.29%.

  • [By Paul Ausick]

    The Coca-Cola Co. (NYSE: KO) traded up 1.15% at $44.90X. The stock’s 52-week range is $39.88 to $46.01. Volume was about 45% below the daily average of around 12.8 million. The company had no specific news.

  • [By Craig Jones]

    On CNBC's "Fast Money Halftime Report," Pete Najarian said that he noticed unusually high bullish options activity in The Coca-Cola Co (NYSE: KO).

  • [By Paul Ausick]

    The Coca-Cola Co. (NYSE: KO) traded down 0.80% at $45.07. The stock’s 52-week range is $39.88 to $46.06. Volume was around 35% below the daily average of about 11.6 million shares. The company had no specific news.

  • [By Paul Ausick]

    The Coca-Cola Co. (NYSE: KO) traded down 0.85% at $87.24. The stock’s 52-week range is $39.88 to $47.13. Volume was about 30% below the daily average of around 13.8 million shares. Analysts at Goldman Sachs cut the stock’s rating to Sell this morning.

  • [By ]

    The issues follow a major headache faced by the fast-growing video unit beginning in March 2017, when a group of brands including Coca-Cola, (KO) Walmart (WMT) and AT&T (T) fled the platform due to ads showing up next to offensive content. Giant advertiser Procter and Gamble (PG) only returned to advertising on YouTube this week, albeit on a more limited basis than before. 

Top 10 Stocks To Buy For 2018: SPDR S&P MidCap 400 ETF (MDY)

Advisors’ Opinion:

  • [By WWW.GURUFOCUS.COM]

    For the details of Cougar Global Investments Ltd’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Cougar+Global+Investments+Ltd

    These are the top 5 holdings of Cougar Global Investments LtdSPDR MidCap Trust Series I (MDY) – 134,036 shares, 37.74% of the total portfolio. Shares added by 9.81%SPDR S&P 500 (SPY) – 150,252 shares, 31.92% of the total portfolio. Shares added by 359.35%iShares Core S&P Small-Cap (IJR) – 374,523 shares, 23.35% of the total portfolio. Shares added by 283.37%iShares MBS (MBB) – 37,334 shares, 3.59% of the total portfolio. Shares added by 109.88%iShares Core U.S. Aggregate Bond (AGG) – 34,781 shares, 3.4% of the

  • [By WWW.GURUFOCUS.COM]

    For the details of REGENTS OF THE UNIVERSITY OF CALIFORNIA’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=REGENTS+OF+THE+UNIVERSITY+OF+CALIFORNIA

    These are the top 5 holdings of REGENTS OF THE UNIVERSITY OF CALIFORNIAiShares J.P. Morgan USD Emerging Markets Bond ETF (EMB) – 229,390 shares, 55.6% of the total portfolio. New PositionThe Estee Lauder Companies Inc (EL) – 33,400 shares, 7.5% of the total portfolio. Exxon Mobil Corp (XOM) – 33,600 shares, 5.74% of the total portfolio. SPDR MidCap Trust Series I (MDY) – 5,600 shares, 3.8% of the total portfolio. New PositionAir Products & Chemicals Inc (APD) – 10,200 shares, 3.21% of the total portfolio. New Purch

Top 10 Stocks To Buy For 2018: The Michaels Companies, Inc.(MIK)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Earnings of note in the coming week include Analogic (ALOG) and Ascena Retail (ASNA) on Monday; Bojangles (BOJA) , H&R Block (HRB) , and Dick’s Sporting Goods (DKS) , Michaels (MIK) , and Urban Outfitters (URBN) on Tuesday; Ciena (CIEN) , Bankrate (RATE) , Express (EXPR) , Vera Bradley (VRA) , and Bob Evans Farms (BOBE) on Wednesday; El Pollo Loco (LOCO) , Hugo Boss (BOSSY) , Party City (PRTY) , Signet Jewelers (SIG) , and Verifone Systems (PAY) on Thursday; and Kirkland’s (KIRK) , and Vail Resorts (MTN) on Friday.

  • [By Laurie Kulikowski]

    We rate MICHAELS COS INC as a Sell with a ratings score of D+. This is driven by some concerns, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. Among the areas we feel are negative, one of the most important has been weak operating cash flow. 

  • [By Chris Lange]

    Michaels Companies Inc. (NASDAQ: MIK) reported its fiscal third-quarter financial results before the markets opened on Thursday. The company said that it had $0.44 in earnings per share (EPS) and $1.24 billion in revenue. The consensus estimates from Thomson Reuters had called for $0.43 in EPS and revenue of $1.26 billion. The same period of last year reportedly had EPS of $0.40 and $1.23 billion in revenue.

  • [By JPMorgan]

    MIK’s results over the past year point to the company’s success in improving merchandising, marketing, and in-store execution plus the benefits of having a functioning e-commerce website. We believe part of the challenge for the bears is both a lack of appreciation for the category as well as missing the historical context of how leadership has evolved. Indeed, the difference in focus on "the front end" under CEO Chuck Rubin (who arrived in 2013) vs. a more process-oriented and margin-focused CEO prior to his arrival left a lot of impactful, low hanging fruit opportunities. Finally, while we acknowledge that longer term the sustainable comp is lower than the recent ~4% underlying trend, we point to the low volatility of sales, high cash generative nature of the business, barriers to entry (e.g., high SKU density, low inventory turns, lack of brands), and MIK’s market leadership as reasons why the multiple has the potential to expand over time (a la AZO). Balance sheet de-levering should also make the PE look increasingly cheap over time and transfer cash/value to equity holders. 

  • [By Jim Cramer]

    42.37% is the gross profit margin for MICHAELS COS INC which we consider to be strong. Regardless of MIK’s high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, the net profit margin of 6.57% trails the industry average.

    MICHAELS COS INC has improved earnings per share by 19.4% in the most recent quarter compared to the same quarter a year ago. This year, the market expects an improvement in earnings ($1.70 versus $1.04).

     

Top 10 Stocks To Buy For 2018: Antares Pharma, Inc.(ATRS)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Friday, healthcare shares fell 0.32 percent. Meanwhile, top losers in the sector included Antares Pharma Inc (NASDAQ: ATRS), down 38 percent, and Infinity Pharmaceuticals Inc. (NASDAQ: INFI) down 16 percent.

Top 10 Stocks To Buy For 2018: TNR Gold Corp. (TRRXF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    ILC is fully funded to at least the end of 2017. They have reasonable insider ownership (Chairman/CEO/President Kirill Klip owns 9.98%), partner ownership (Ganfeng 19%), plus TNR Gold (OTC:TRRXF) with 17.1% are the top 3 shareholders.

Top 10 Stocks To Buy For 2018: Adient plc (ADNT)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Western Digital (WDC) , Twilio (TWLO) , Adient (ADNT) , Salesforce.com (CRM) , AT&T (T) and Verizon (VZ) .

Top Biotech Stocks To Invest In 2018

When Amgen Inc. (NASDAQ: AMGN) reported its third-quarter financial results after the markets closed on Thursday, the company said that it had $3.02 in earnings per share (EPS) and $5.81 billion in revenue. Consensus estimates from Thomson Reuters had called for $2.79 in EPS and revenue of $5.74 billion. In the same period of last year, the biotech giant posted EPS of $2.72 and $5.72 billion in revenue.

In terms of guidance for the full year, the company expects to have EPS in the range of $11.40 to $11.55 and revenues between$22.6 billion and $22.8 billion. Both forecasts increased from their previous levels. The consensus estimates for the full year are $11.36 in EPS and $22.77 billion in revenue.

The company generated $2.5 billion of free cash flow in the third quarter, compared with $2.8 billion in the third quarter of 2015. The board of directors declared a dividend of $1.00 per share on October 14 that will be paid on December 8 to all stockholders of record as of November 16.

Top Biotech Stocks To Invest In 2018: Trevena, Inc.(TRVN)

Advisors’ Opinion:

  • [By Paul Ausick]

    Trevena Inc. (NASDAQ: TRVN) dropped about 6.3% Thursday, to post a new 52-week low of $3.70 after closing at $3.95 on Wednesday. The stock’s 52-week high is $9.73. Volume was nearly 5 times the daily average of around 700,000 shares. The company’s pain-killing drug got mixed results in a trial result reported Tuesday.

  • [By Lisa Levin] Gainers
    Trevena Inc (NASDAQ: TRVN) rose 10.8 percent to $3.60 in pre-market trading after dropping 4.97 percent on Wednesday.
    Yum China Holdings Inc (NYSE: YUMC) rose 10.2 percent to $31.05 in pre-market trading after the company reported upbeat earnings for its first quarter.
    Seres Therapeutics Inc (NASDAQ: MCRB) rose 9.1 percent to $11.39 in pre-market trading after dropping 5.26 percent on Wednesday.
    Plug Power Inc (NASDAQ: PLUG) rose 8.9 percent to $2.45 in pre-market trading after surging 73.08 percent on Wednesday.
    Coach Inc (NYSE: COH) rose 6.7 percent to $41.98 in pre-market trading. Coach named Ian Bickley as President, Global Business Development and Strategic Alliances.
    Sapiens International Corporation N.V. (NASDAQ: SPNS) shares rose 6.1 percent to $13.91 in pre-market trading after gaining 0.54 percent on Wednesday.
    Jazz Pharmaceuticals plc (NASDAQ: JAZZ) rose 6.1 percent to $149.15 in pre-market trading. Jazz Pharma reached a settlement with Hikma Pharma related to Xyrem patent case. Mizuho downgraded Jazz from Buy to Neutral.
    Interactive Brokers Group, Inc. (NASDAQ: IBKR) shares rose 6 percent to $36.72 in pre-market trading after declining 0.03 percent on Wednesday.
    Rewalk Robotics Ltd (NASDAQ: RWLK) rose 5.3 percent to $2.00 in pre-market trading after the company disclosed that the U.S. Department of Veterans Affairs purchased 28 added Exoskeleton Systems.
    Merrimack Pharmaceuticals Inc (NASDAQ: MACK) rose 5.1 percent to $3.29 in pre-market trading. Merrimack declared a $1.06 special dividend.
    BioTime, Inc. (NYSE: BTX) shares rose 4.8 percent to $3.50 in pre-market trading. BioTime, reported the formation of new subsidiary AgeX Therapeutics, Inc.
    Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) shares rose 4.8 percent to $12.26 in pre-market trading after gaining 0.69 percent on Wednesday.
    Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 3.6 percent to $39.15 in pre-market trading after the company posted better-than
  • [By Lisa Levin]

    Trevena Inc (NASDAQ: TRVN) shares dropped 36 percent to $4.55 despite a positive development in Phase 3 trials. Trevena announced positive top-line results from ongoing Phase 3 trials called "APOLLO-1" and "APOLLO-2." The studies evaluated the safety of Trevena's oliceridine therapy in patients for 48 hours following bunionectomy and 24 hours following abdominoplasty.

Top Biotech Stocks To Invest In 2018: Flextronics International Ltd.(FLEX)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows Sanmina Corp along with potential peersCelestica Inc (NYSE: CLS), Jabil Circuit, Inc (NYSE: JBL) and Flextronics International Ltd (NASDAQ: FLEX)all having similar looking charts; but SANM has been the outperformer:

  • [By Peter Graham]

    Mid cap electronic manufacturing services (EMS) stock Flextronics International Ltd (NASDAQ: FLEX) reported Q1 2017 earnings after the market closed on Thursday with results missing Wall Street expectations and shares falling in afterhours/premarket trading. Net sales grew 2% to $6.0 billion and GAAP net income was approximately $125 millionversus net income of $106 million. The CEO commented:

  • [By Peter Graham]

    A long term performance chart shows shares of mid cap Jabil Circuit and small capCelestica Inc (NYSE: CLS) heading back into positive territory while shares of mid cap Flextronics International Ltd (NASDAQ: FLEX) and small capSanmina Corp (NASDAQ: SANM) (a previous SmallCap Network Elite Opportunitynewslettersuggestion as the next breakout stock) have been much better performers as they took off early last year:

  • [By Amber Hestla, Michael J. Carr]

    Among its suppliers is Flextronics International (Nasdaq: FLEX), which offers a variety of engineering services and provides supply chain management. Other Flextronics customers include Hewlett-Packard (NYSE: HPQ), LG and Google's (Nasdaq: GOOG) Motorola Mobility. 

Top Biotech Stocks To Invest In 2018: National Grid Transco, PLC(NGG)

Advisors’ Opinion:

  • [By Travis Hoium]

    National Grid (NYSE:NGG) came out with some interesting information last week, saying 2.4 GW of distributed solar was added in the U.K. between February 2016 and February 2017 and another 1.5 GW is expected in the next year. The U.K. isn’t exactly a hotbed for solar activity, but it’s growing as an important market.

  • [By Lisa Levin]

    Tuesday afternoon, the utilities sector proved to be a source of strength for the market. Leading the sector was strength from National Grid plc (ADR) (NYSE: NGG) and Dominion Resources, Inc. (NYSE: D).

  • [By WWW.MONEYSHOW.COM]

    Among utilities, National Grid (NGG) is my best pick for 2017, as it’s an almost perfect hedge against uncertainty. It’s insulated from changes in government interest rates. It can be both an inflation hedge and a play on a strong dollar.

  • [By Tyler Crowe, Dan Caplinger, and Neha Chamaria]

    We asked three of our contributors to highlight a stock they see as a dividend stock to buy in February. They responded with automaker Ford Motors (NYSE:F), oil and gas logistics company Enterprise Products Partners (NYSE:EPD), and electricity transmission specialist National Grid (NYSE:NGG). Here’s a quick run-down as to why investors should take a look at these high-yield stocks.

Top Stocks To Own For 2018

Pondering Snap’s IPO over laser tag and paintball Even concerns about Snapchat’s slowing user growth aren’t stopping investors from clamoring for its stock.

Snap, the parent company of Snapchat, priced its initial public offering at $17 a share on Wednesday. It had previously proposed a range of $14 to $16 a share.

That will reportedly give Snap a market value of nearly $24 billion, making it the largest U.S. tech IPO since Facebook (FB, Tech30).

Reps for Snap did not immediately respond to a request for comment.

“The demand for the Snap IPO has been very, very strong,” says Jeff Zell, an analyst with IPO Boutique, a research firm. “Even the original naysayers and detractors from the deal have pretty much softened their negativity.”

Top Stocks To Own For 2018: Vitality Biopharma (VBIO)

Advisors’ Opinion:

  • [By Jim Robertson]

    That’s why its worth pointing out that just yesterday, small cap cannabinoid prodrug pharmaceutical stock Vitality Biopharma, Inc. (OTCQB: VBIO) announced the appointment of Tracy Rockney, J.D. to the position of Senior Regulatory Advisor. In addition to being the Co-Founder & Chief Operating Officer of OneSource Regulatory, a regulatory consulting firm, Rockney was previously:

  • [By James E. Brumley]

    Investors who were looking to learn a little more about up-and-coming drug development company Vitality Biopharma Inc (OTCMKTS:VBIO) may want to mark December 8th on their calendar…. if they’re going to be in the Los Angeles area that day anyway. The company will be making a presentation that day, at the annual LD Micro Main Event. Interested and approved investors can attend the VBIO presentation by registering beforehand with LD Micro.

    Vitality Biopharma has found a way to make cannabinoid-based pharmaceuticals without the usual downside of cannabinoids. Namely, Vitality Biopharma’s version of cannabinoids are non-psychotropic, meaning larger, more effective dosing is possible without the ‘high’. It’s this little detail that takes cannabinoid medicine — already the most compelling frontier in the world of pharma — to the next level. There’s a reason some people think the cannabinoid market could be worth $20 billion by 2020.

    The idea was significantly advanced in early November. In eight of the nine states voters were asked about legalization of marijuana (for one reason or another), voters said yes….. four for recreational use, and four for medical use. In eight of those nine states, the measures passed. Marijuana is legal in more than half the United States now, and we’re en route to a decided majority in the foreseeable future.

    VBIO didn’t necessarily need a sweeping victory at the ballot box, but each time marijuana wins, it seems to advance the discussion of the power of cannabinoids as medicine.

    Investors will be able to learn more about Vitality Biopharma’s work in that arena on Thursday of this week. On that day — 8 AM PST / 11 AM EST — at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Robert Brooke, CEO of Vitality Biopharma, will be making a presentation as well as meeting with current and prospective investors.

    LD Micro was founded in 2006 with the sole purpose of being an independent resource in t

  • [By James E. Brumley]

    In mid-September, Vitality Biopharma Inc (OTCMKTS:VBIO) announced it was going to take aim at the development of an alternative to opioids as a means of treating pain. At the time, there was little doubt that the company’s cannabinoid science was capable of doing so. What wasn’t clear to VBIO shareholders was exactly how that might happen…. meaning what sort of drug might Vitality Biopharma come up with.

    We got the first of what will likely be several answers to the question today. Per today’s press release, Vitality Biopharma intends to come up with a treatment for narcotic bowel syndrome, which is a severe form of (ironically enough) opiate-induced abdominal pain.

    As a refresher, Vitality Biopharma was the name we introduced to you back on August 8th, pointing out it had developed a whole new way of making cannabinoid-based medicines. Their versions offer all the upsides of cannabinoids, but without the psychotropic (“getting high’) effects, and without some of the common downsides associated with these pharmaceuticals… like mouth and skin lesions.

    There are even bigger advantages to Vitality Biopharma’s science, however. Namely, since these drugs are prodrugs and aren’t activated until in the body, they allow for targeted delivery to the GI tract (yet can also selectively target other body parts, even as far away from the GI tract as the brain). Perhaps more than anything though, these drugs are orally-administered by virtue of being highly soluble, making them easy to use.

    It’s this nuance that makes Vitality Biopharma’s recently-announced intention so interesting, and compelling.

    Studies have found that up to 81% of patients treated with opiates have functional bowel disorders, with more than half — 58% to be exact — of opiate users reporting chronic abdominal pain stemming from the use of their prescribed painkillers. Considering 200 million opioid prescriptions are filled every year in the United States alo

  • [By Phil Saunders]

    Vitality Biopharma, Inc. (OTCBB: VBIO) recent ascent as a strong small cap player in Cannabis pharma, is part of a boom in Cannabis-based pharmaceuticals making announcements about unique and innovative delivery systems being tested for such ailments as Epilepsy, Multiple Sclerosis, and Crohns disease. But it is important to understand how the industry is evolving in the United States and Canada and what that might mean when realizing valuation and the evolution of government policies which still vary from jurisdiction to jurisdiction, making access to Cannabis and the pricing model still a big question moving forward.

  • [By Matthew Briar]

    Back in September, Vitality Biopharma Inc (OTCMKTS:VBIO) CEO Robert Brooke officially announced his company would be entering the painkiller market, specifically taking aim at the development of an alternative to opioids. His specific words? “Opiates are one of the key classes of drugs we’re seeking to replace, or to make far less necessary, as our proprietary cannabosides could provide a potent alternative form of pain relief and help avoid, or greatly reduce, the use of opiates for the treatment of many conditions…”

Top Stocks To Own For 2018: On Assignment Inc.(ASGN)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Thursday, our Under the Radar Moversnewslettersuggested suggested small cap employment services stockOn Assignment, Inc (NYSE: ASGN) as a short trade thats already turned profitable for us:

Top Stocks To Own For 2018: Technology Select Sector SPDR ETF (XLK)

Advisors’ Opinion:

  • [By ]

    What My System Flagged As A Buy This Week
    It’s no secret that the technology sector has had an incredible year so far — the SPDR Technology Select ETF (NYSE: XLK) is up over 31% year-to-date, compared with the S&P 500’s 14% return.

  • [By Craig Jones]

    Kevin Kelly, the managing partner at Kelly & Co., spoke on Bloomberg Markets about a bullish options trade in Technology Select Sector SPDR Fund (NYSE: XLK).

  • [By Wayne Duggan]

    High-flying tech stocks were hammered Wednesday, sending the Technology Select Sector SPDR Fund (NYSE: XLK) down more than 2.5 percent and the Nasdaq down 1.4 percent, its worst day of trading since August 17.

  • [By Money Morning News Team]

    If the price is keeping you out of GOOGL, take a look at theTechnology SPDR ETF (NYSE Arca: XLK), where you get to hold shares of many of these top tech companies at a fraction of the cost.

Top Stocks To Own For 2018: Dunkin' Brands Group, Inc.(DNKN)

Advisors’ Opinion:

  • [By WWW.USATODAY.COM]

    While McDonald’s (NYSE: MCD) and Dunkin’ Brands’ (NASDAQ: DNKN) Dunkin’ Donuts both now sell premium espresso-based beverages along with other fancy coffee drinks, people don’t view those brands the way they see Starbucks. The Seattle-based coffee chain exists in its own world, where it can sell out of $10 cups of whisky-barrel-aged coffee while it opens more than a thousand Reserve stores selling pricier drinks than its normal, already expensive beverage lineup.

  • [By Ben Levisohn]

    Dunkin’ Brands Group (DNKN) has dropped 3.5% to $54.16 after getting cut to Sell from Neutral at Goldman Sachs.

    Morgan Stanley (MS) has risen 1.1% to $42.95 after getting upgraded to Buy from Hold at Deutsche Bank.

  • [By Ben Levisohn]

    The market is treating Chipotle as if it is an Amazon, Tesla, Apple or Google, when in fact all they do is make burritos. With the money it would cost you to buy Chipotle today @ $14 billion dollars you could buy Wendy’s (WEN), Cheesecake Factory (CAKE), Papa John’s International (PZZA), and Dunkin’ Brands (DNKN). Chipotle would need to generate at least $24 in earnings per share in order to justify the current market cap — they are not even expected to generate half of that next year. Chipotle is expected to report Q1 on April 25 and the market, in my opinion, has already more than priced in good news.

  • [By John Udovich]

    While theMacys Thanksgiving Day parade sponsored by Macy’s, Inc (NYSE:M) is the most well known corporate sponsoredThanksgiving parade,Dunkin Brands Group Inc (NASDAQ:DNKN) and McDonald’s Corporation (NYSE:MCD) also sponsor parades in major USA cities that will help them grab some extra consumer attention and perhaps help the bottom line a bit.

Top Stocks To Own For 2018: Trevena, Inc.(TRVN)

Advisors’ Opinion:

  • [By Maxx Chatsko]

    Shares of clinical-stage biopharma Trevena (NASDAQ:TRVN) fell nearly 12% today after it reported full-year 2016 earnings. The pre-revenue company didn’t announce any surprises one way or the other. However, investors appear to be considering the near-term consequences of swelling expenses that won’t be offset by product sales anytime soon.

  • [By Paul Ausick]

    Trevena Inc. (NASDAQ: TRVN) dropped about 6.3% Thursday, to post a new 52-week low of $3.70 after closing at $3.95 on Wednesday. The stock’s 52-week high is $9.73. Volume was nearly 5 times the daily average of around 700,000 shares. The company’s pain-killing drug got mixed results in a trial result reported Tuesday.

  • [By Lisa Levin] Gainers
    Trevena Inc (NASDAQ: TRVN) rose 10.8 percent to $3.60 in pre-market trading after dropping 4.97 percent on Wednesday.
    Yum China Holdings Inc (NYSE: YUMC) rose 10.2 percent to $31.05 in pre-market trading after the company reported upbeat earnings for its first quarter.
    Seres Therapeutics Inc (NASDAQ: MCRB) rose 9.1 percent to $11.39 in pre-market trading after dropping 5.26 percent on Wednesday.
    Plug Power Inc (NASDAQ: PLUG) rose 8.9 percent to $2.45 in pre-market trading after surging 73.08 percent on Wednesday.
    Coach Inc (NYSE: COH) rose 6.7 percent to $41.98 in pre-market trading. Coach named Ian Bickley as President, Global Business Development and Strategic Alliances.
    Sapiens International Corporation N.V. (NASDAQ: SPNS) shares rose 6.1 percent to $13.91 in pre-market trading after gaining 0.54 percent on Wednesday.
    Jazz Pharmaceuticals plc (NASDAQ: JAZZ) rose 6.1 percent to $149.15 in pre-market trading. Jazz Pharma reached a settlement with Hikma Pharma related to Xyrem patent case. Mizuho downgraded Jazz from Buy to Neutral.
    Interactive Brokers Group, Inc. (NASDAQ: IBKR) shares rose 6 percent to $36.72 in pre-market trading after declining 0.03 percent on Wednesday.
    Rewalk Robotics Ltd (NASDAQ: RWLK) rose 5.3 percent to $2.00 in pre-market trading after the company disclosed that the U.S. Department of Veterans Affairs purchased 28 added Exoskeleton Systems.
    Merrimack Pharmaceuticals Inc (NASDAQ: MACK) rose 5.1 percent to $3.29 in pre-market trading. Merrimack declared a $1.06 special dividend.
    BioTime, Inc. (NYSE: BTX) shares rose 4.8 percent to $3.50 in pre-market trading. BioTime, reported the formation of new subsidiary AgeX Therapeutics, Inc.
    Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) shares rose 4.8 percent to $12.26 in pre-market trading after gaining 0.69 percent on Wednesday.
    Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 3.6 percent to $39.15 in pre-market trading after the company posted better-than
  • [By Lisa Levin]

    Trevena Inc (NASDAQ: TRVN) shares dropped 36 percent to $4.55 despite a positive development in Phase 3 trials. Trevena announced positive top-line results from ongoing Phase 3 trials called "APOLLO-1" and "APOLLO-2." The studies evaluated the safety of Trevena's oliceridine therapy in patients for 48 hours following bunionectomy and 24 hours following abdominoplasty.

  • [By Chris Lange]

    Trevena Inc. (NASDAQ: TRVN) reported positive results from two late-stage clinical trials that work to treat post-surgical pain. The company intends to submit these results to the FDA for a marketing approval agreement in the fourth quarter. Previously, oliceridine was approved for a breakthrough designation by the agency.

Top 5 Warren Buffett Stocks To Invest In 2018

Both Amazon.com (NASDAQ:AMZN) and Google’s parent company,Alphabet (NASDAQ:GOOG) (NASDAQ:GOOGL), are trading near their all-time highs. Amazon’s stock has climbed so much in the past 12 months, it’s made its founder and CEO Jeff Bezos the second wealthiest person in the world, recently surpassing Warren Buffett and Amancio Ortega. Alphabet shares are up a modest 11%, compared with Amazon’s 51% increase.

But investors can’t dwell too much on the past. They need to look to the future to determine which stocks offer the best opportunities for further gains. Today we’ll compare the two tech giants head to head to determine which is a better buy: Amazon.com or Alphabet.

Image source: Amazon.com.

Amazon is firing on all cylinders

Amazon’s core retail business is strong. It generated $124 billion in revenue in 2016 across its North American and international retail segments. That’s up 25% from $99 billion in 2015. Amazon’s growth is fueled by increasing Prime membership, which acts as a huge incentive for both customers and merchants to use Amazon’s marketplace before looking elsewhere. A survey from BloomReach found that 55% of online shoppers begin their product search on Amazon.com.

Top 5 Warren Buffett Stocks To Invest In 2018: TheStreet, Inc.(TST)

Advisors’ Opinion:

  • [By Lisa Levin] Companies Reporting Before The Bell
    Tyson Foods, Inc. (NYSE: TSN) is expected to report quarterly earnings at $1.38 per share on revenue of $9.86 billion.
    Aecom (NYSE: ACM) is projected to report quarterly earnings at $0.71 per share on revenue of $4.67 billion.
    JD.Com Inc(ADR) (NASDAQ: JD) is estimated to report quarterly earnings at $0.11 per share on revenue of $12.60 billion.
    58.com Inc (ADR) (NYSE: WUBA) is projected to report quarterly earnings at $0.28 per share on revenue of $383.60 million.
    Kamada Ltd (NASDAQ: KMDA) is expected to report quarterly earnings at $0.02 per share on revenue of $25.00 million.
    Palatin Technologies, Inc. (NYSE: PTN) is projected to report quarterly earnings at $0.06 per share on revenue of $28.00 million.
    TheStreet, Inc. (NASDAQ: TST) is estimated to report a quarterly loss at $0.02 per share on revenue of $15.81 million.
    Atlantica Yield PLC (NASDAQ: ABY) is projected to report quarterly earnings at $0.45 per share on revenue of $290.80 million.
    Asure Software Inc (NASDAQ: ASUR) is estimated to report quarterly earnings at $0.15 per share on revenue of $15.26 million.
    Cyren Ltd (NASDAQ: CYRN) is expected to report quarterly loss at $0.06 per share on revenue of $7.90 million.
    Viewray Inc (NASDAQ: VRAY) is estimated to report quarterly loss at $0.12 per share on revenue of $18.58 million.

     

  • [By Steven Goldberg]

    Launched in August 2001, Action Alerts PLUS Portfolio has been a centerpiece of the financial advice offered by TheStreet.com. The website belongs to TheStreet, Inc. (TST), a publicly traded company that Cramer co-founded in 1996. PLUS Portfolio subscribers, who pay $15 a month, always get the recommendations before Cramer buys them for the portfolio, the Wharton paper reports. Likewise, subscribers get Cramers picks before he airs them on Mad Money.

Top 5 Warren Buffett Stocks To Invest In 2018: Acacia Communications, Inc. (ACIA)

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap networking stock Acacia Communications (NASDAQ: ACIA) is the second most shorted stock on the Nasdaq with short interest of 54.23% according to Highshortinterest.com. Acacia Communications is a small cap developer, manufacturers and seller high-speed coherent optical interconnect products that are designed to transform communications networks through improvements in performance, capacity and cost. By leveraging silicon technology to build optical interconnects, a process Acacia Communications refers to as the siliconization of optical interconnect, the Company is able to offer products at higher speeds and density with lower power consumption, that meet the needs of cloud and service providers and can be easily integrated in a cost-effective manner with existing network equipment.

  • [By Scott Rubin]

    Shares of Acacia Communications, Inc. (NASDAQ: ACIA) soared on the back of the company's second-quarter earnings results, closing the session up 41 percent to $95.67. Planet Fitness Inc (NYSE: PLNT) added 10 percent after reporting better-than expected results. The stock closed at $22.36. Steel stocks fell during Friday's session. United States Steel Corporation (NYSE: X) lost 7 percent to $21.06 and AK Steel Holding Corporation (NYSE: AKS) fell 6 percent to $5.03.

  • [By Lisa Levin]

    Acacia Communications, Inc. (NASDAQ: ACIA) was down, falling around 14 percent to $54.34 after the company issued a weak forecast for the current quarter. However, the company’s Q4 results exceeded expectations.

  • [By Evan Niu, CFA]

    Shares of optical component companies have dropped today, includingOclaro (NASDAQ:OCLR), Acacia (NASDAQ:ACIA), Lumentum (NASDAQ:LITE), and Finisar (NASDAQ:FNSR), whose shares were down 11%, 11%, 6%, and 3%, respectively, as of 3:30 p.m. EDT, after the U.S. broadened its investigation regarding compliance with sanctions programs.

Top 5 Warren Buffett Stocks To Invest In 2018: Trevena, Inc.(TRVN)

Advisors’ Opinion:

  • [By Paul Ausick]

    Trevena Inc. (NASDAQ: TRVN) dropped about 6.3% Thursday, to post a new 52-week low of $3.70 after closing at $3.95 on Wednesday. The stock’s 52-week high is $9.73. Volume was nearly 5 times the daily average of around 700,000 shares. The company’s pain-killing drug got mixed results in a trial result reported Tuesday.

  • [By Maxx Chatsko]

    Shares of clinical-stage biopharma Trevena (NASDAQ:TRVN) fell nearly 12% today after it reported full-year 2016 earnings. The pre-revenue company didn’t announce any surprises one way or the other. However, investors appear to be considering the near-term consequences of swelling expenses that won’t be offset by product sales anytime soon.

  • [By Chris Lange]

    Trevena Inc. (NASDAQ: TRVN) reported positive results from two late-stage clinical trials that work to treat post-surgical pain. The company intends to submit these results to the FDA for a marketing approval agreement in the fourth quarter. Previously, oliceridine was approved for a breakthrough designation by the agency.

Top 5 Warren Buffett Stocks To Invest In 2018: Novellus Systems Inc.(NVLS)

Advisors’ Opinion:

  • [By Chris Lange]

    Nivalis Therapeutics, Inc. (NASDAQ: NVLS) is watching its shares crumble on Tuesday after the company gave an update on its mid-stage Cystic Fibrosis (CF) trial. Specifically, the company announced topline results from the its Phase 2 trial evaluating the efficacy and safety of two doses of cavosonstat, in adult patients with CF who had two copies of the F508del-CFTR mutation and were being treated with Orkambi.

  • [By Lisa Levin]

    Nivalis Therapeutics Inc (NASDAQ: NVLS) shares dropped 59 percent to $2.58 after the company reported it failed to demonstrate benefit in absolute change in predicted FEV1 or in Sweat Chloride Reduction at 12 weeks. The failed trial has prompted four Wall Street firms to downgrade the issue including Raymond James, Cowen, Baird and Stifel.

  • [By Paul Ausick]

    Nivalis Therapeutics Inc. (NASDAQ: NVLS) dropped 60% on Tuesday to post a new 52-week low of $2.50 after closing at $6.25 on Monday. The stock’s 52-week high is $9.45. Volume of about 4.2million was about 60 times the daily average of around 75,000 shares. The company reported a failed mid-stage trial on its treatment for cystic fibrosis.

Top 5 Warren Buffett Stocks To Invest In 2018: Credit Suisse Group(CS)

Advisors’ Opinion:

  • [By Paul R. La Monica]

    European banks worse off than 2008? Lamensdorf is concerned about the exposure to bad loans (especially energy company debt) held by big banks such as Royal Bank of Scotland (RBS), Credit Suisse (CS) and Deutsche Bank (DB). He’s shorting all three.

  • [By Money Morning News Team]

    That’s why Krauth predicts the price of gold will hit $1,400 by the end of the year. Many analysts from banks likeCredit SuisseGroup AG (NYSE ADR: CS) even see gold going as high as $1,500.

  • [By Wayne Duggan] Related DB Deutsche Bank In The Tank Mike Khouw Sees Unusual Options Activity In Deutsche Bank 33 Large Banks On The Federal Reserve's Radar In 2016 (Seeking Alpha)
    Related CS Earnings Scheduled For February 4, 2016 Blockchain Moves Forward In The Financial Industry Credit Suisse Group AG (CS) Tidjane Thiam on Q4 2015 Results – Earnings Call Transcript (Seeking Alpha)

    The latest credit default swap (CDS) data from BMO Capital Markets indicate a number of investors are growing increasingly concerned about the one-year outlook for capital markets. In a new report, analyst Mark Steele discussed the recent surge in one-year CDS activity, and what it means for the market.